AU2009258775B2 - MYBL2 epitope peptides and vaccines containing the same - Google Patents

MYBL2 epitope peptides and vaccines containing the same Download PDF

Info

Publication number
AU2009258775B2
AU2009258775B2 AU2009258775A AU2009258775A AU2009258775B2 AU 2009258775 B2 AU2009258775 B2 AU 2009258775B2 AU 2009258775 A AU2009258775 A AU 2009258775A AU 2009258775 A AU2009258775 A AU 2009258775A AU 2009258775 B2 AU2009258775 B2 AU 2009258775B2
Authority
AU
Australia
Prior art keywords
peptide
peptides
present
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009258775A
Other languages
English (en)
Other versions
AU2009258775A1 (en
Inventor
Ryuji Ohsawa
Takuya Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AU2009258775A1 publication Critical patent/AU2009258775A1/en
Application granted granted Critical
Publication of AU2009258775B2 publication Critical patent/AU2009258775B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009258775A 2008-06-10 2009-06-09 MYBL2 epitope peptides and vaccines containing the same Ceased AU2009258775B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6029308P 2008-06-10 2008-06-10
US61/060,293 2008-06-10
PCT/JP2009/002587 WO2009150822A1 (en) 2008-06-10 2009-06-09 Mybl2 epitope peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
AU2009258775A1 AU2009258775A1 (en) 2009-12-17
AU2009258775B2 true AU2009258775B2 (en) 2013-10-10

Family

ID=41416535

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009258775A Ceased AU2009258775B2 (en) 2008-06-10 2009-06-09 MYBL2 epitope peptides and vaccines containing the same

Country Status (13)

Country Link
US (1) US20110189213A1 (enExample)
EP (1) EP2297180A4 (enExample)
JP (1) JP2011522777A (enExample)
KR (1) KR20110016952A (enExample)
CN (1) CN102119170A (enExample)
AU (1) AU2009258775B2 (enExample)
BR (1) BRPI0913436A2 (enExample)
CA (1) CA2727482A1 (enExample)
IL (1) IL209870A0 (enExample)
MX (1) MX2010013688A (enExample)
RU (1) RU2496787C2 (enExample)
TW (1) TW201000119A (enExample)
WO (1) WO2009150822A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
CN104017054B (zh) * 2014-06-25 2016-12-07 南安市威速电子科技有限公司 Per2蛋白激动剂多肽及其应用
CN104004062B (zh) * 2014-06-25 2016-03-16 刘元超 关于per2蛋白激动剂多肽及其应用
CN104045693B (zh) * 2014-06-25 2016-12-07 杨高林 一种关于per2蛋白激动剂多肽及其应用
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
WO2017203370A2 (en) * 2016-05-23 2017-11-30 The Council Of The Queensland Institute Of Medical Research Cmv epitopes
CN109963862B (zh) * 2016-09-07 2024-01-30 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253486A (ja) * 1988-08-19 1990-02-22 Rikagaku Kenkyusho ヒトｍｙｂ関連遺伝子
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
WO2004018667A1 (ja) * 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
CN101139392B (zh) * 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN1703522A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2947160B1 (en) * 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
AU2005304878B2 (en) * 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CN101500597A (zh) * 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2295571A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007066423A1 (ja) * 2005-12-08 2007-06-14 Dainippon Sumitomo Pharma Co., Ltd. Ａｍａｃｒ由来の腫瘍抗原ペプチド
JP2009091249A (ja) * 2006-01-23 2009-04-30 Univ Kurume Ｃ型肝炎ウイルス２ａ由来ＨＬＡ−Ａ２拘束性抗原ペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Powzaniuk et al. "B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells" The Journal of Immunology (2001) 167: 242-249 *

Also Published As

Publication number Publication date
JP2011522777A (ja) 2011-08-04
US20110189213A1 (en) 2011-08-04
KR20110016952A (ko) 2011-02-18
TW201000119A (en) 2010-01-01
MX2010013688A (es) 2011-02-23
CN102119170A (zh) 2011-07-06
EP2297180A4 (en) 2011-11-09
CA2727482A1 (en) 2009-12-17
BRPI0913436A2 (pt) 2015-12-01
RU2496787C2 (ru) 2013-10-27
IL209870A0 (en) 2011-02-28
RU2010154101A (ru) 2012-07-20
AU2009258775A1 (en) 2009-12-17
EP2297180A1 (en) 2011-03-23
WO2009150822A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
AU2009261382B2 (en) CDCA1 epitope peptides and vaccines containing the same
US8367799B2 (en) TEM8 peptides and vaccines comprising the same
US20110280898A1 (en) Inhbb epitope peptides and vaccines containing the same
AU2009283763B2 (en) HIG2 and URLC10 epitope peptide and vaccines containing the same
AU2009258775B2 (en) MYBL2 epitope peptides and vaccines containing the same
US9193765B2 (en) Melk epitope peptides and vaccines containing the same
WO2009150835A1 (en) Iqgap3 epitope peptides and vaccines containing the same
AU2008238739B2 (en) TEM8 peptides and vaccines comprising the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same
HK1175197B (en) Tem8 peptides and vaccines comprising the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired